Galectin Therapeutics (GALT) Tops Q2 EPS by 4c
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24).
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agree Realty (ADC) Tops Q3 FFO by 4c
- Berkshire Hills Bancorp (BHLB) Misses Q3 EPS by 1c
- Independent Bank Group (IBTX) Tops Q3 EPS by 6c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!